T. Rowe Price Associates
BDTX icon

T. Rowe Price Associates’s Black Diamond Therapeutics BDTX Stock Holding History

T. Rowe Price Associates’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,182
Closed -$22K – 3070
2025
Q1 		$22K Hold
14,182
– – ﹤0.01% 2999
2024
Q4 		$31K Sell
14,182
-365,762
-96% -$1.05M ﹤0.01% 2975
2024
Q3 		$1.65M Sell
379,944
-433,122
-53% -$2.36M ﹤0.01% 1728
2024
Q2 		$3.79M Buy
+813,066
New +$4.36M ﹤0.01% 1305
2020
Q4 		– Sell
-27,028
Closed -$817K – 2671
2020
Q3 		$817K Buy
+27,028
New +$823K ﹤0.01% 1897

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

T. Rowe Price Associates's BDTX Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Black Diamond Therapeutics (BDTX) in Q2 2025, closing a stake of 14,182 shares — an estimated $22K sold.

T. Rowe Price Associates first reported a position in BDTX in Q3 2020 and held it in 5 quarters. The position peaked at $3.79M in Q2 2024. 94 funds tracked by Wall St. Rank hold BDTX as of Q2 2025.

  • T. Rowe Price Associates reported no remaining Black Diamond Therapeutics position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 14,182 Black Diamond Therapeutics shares in Q2 2025, an estimated $22K.
  • T. Rowe Price Associates first reported a position in Black Diamond Therapeutics in Q3 2020 and held it in 5 quarters.
  • T. Rowe Price Associates's Black Diamond Therapeutics position peaked at $3.79M in Q2 2024.
  • 94 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.